Welcome to Bristol Myers Squibb Massachusetts
At Bristol Myers Squibb, our innovative teams have been at the forefront of the scientific collective in Massachusetts for over a decade.
Our workforce has the agility and creativity of an entrepreneurial biotech bolstered by the extensive resources and expertise of our global network. Bristol Myers Squibb currently has R&D locations in Alewife and Cambridge while a new R&D flagship facility is under construction in Cambridge Crossing, at the intersection of Boston, Cambridge and Somerville. In 2023, Bristol Myers Squibb will be combining its two R&D research centers in Cambridge into a new state-of-the-art facility at Cambridge Crossing to foster innovation and create efficiency. The company also operates a biologics development and manufacturing site about 45 minutes from Boston that is being expanded to encompass cell therapy production. By bringing passionate scientists of multiple disciplines together across our sites, we work smarter and faster toward our vision of transforming patients’ lives through science.
Meet our team
Learn about our leaders who are making a difference in Massachusetts.
Emma Lees serves as senior vice president and head of the Mechanisms of Cancer Resistance Thematic Research Center at Bristol Myers Squibb’s Cambridge, MA, site.
Odile Smith serves as vice president and site head for the company’s Devens, MA, facility.
Sharon Cload serves as vice president of Discovery Biotherapeutics, East Coast and is based at Bristol Myers Squibb’s Cambridge, MA, site.
Michael (Mike) Ellis, PhD, leads the team responsible for supporting the identification and optimization of small molecule therapies to help create and advance potentially transformational pipeline assets.
Lisa McClintock serves as vice president and lead at Bristol Myers Squibb’s cell therapy manufacturing facility in Devens, MA.
Robert Plenge serves as senior vice president and head of Translational Medicine and of the Immunology, Cardiovascular and Fibrosis Thematic Research Center at Bristol Myers Squibb’s Cambridge, MA, site.
Cathryn Shaw-Reid serves as the vice president and head of Cell Therapy Global Manufacturing at the company's Devens, MA facility.
Join us as we transform patient lives through science
Every day, each of us work to improve outcomes of patients fighting serious diseases. Together we’re building a better future for each other and the patients who need us the most.
Driving innovation forward in Massachusetts
Learn about our broad scope of scientific innovation in Massachusetts.
Bristol Myers Squibb is at the forefront of manufacturing innovations, and we are proud that our new cell therapy facility in the Boston area will include many next generation technologies and the latest integrated digital system.
Hear from members of the global Bristol Myers Squibb workforce who have remained on-site during the COVID-19 pandemic, what it was like and how the company made them feel safe to continue their work delivering for patients.
The sites at Devens, MA, and Leiden, the Netherlands, will join the existing Bristol Myers Squibb cell therapy manufacturing network to expand global manufacturing capacity to support the promise of cell therapy and bring treatments to patients faster.
Community impact
Learn how we are making a difference in communities across Massachusetts.
Learn more about how Bristol Myers Squibb signed on as a sponsor of Science Club for Girls as part of the company’s commitment to educate, hire, and inspire a new generation of physicians and scientists from communities who have been historically underrepresented in STEM.
Cathryn Shaw-Reid, vice president, Drug Substance Biologics Manufacturing, has spent all of her 20-year career in health industry leadership roles, but her leadership qualities first began to emerge during her high school days on the basketball team and as head of the School’s Leadership Development Steering Committee.
Additional resources
Learn more about our scientific approaches and innovation.
Bristol Myers Squibb is advancing cell therapy research through novel manufacturing approaches and a well-established supply chain platform across a broad network of state-of-the-art facilities with cutting-edge technologies and highly trained manufacturing teams.